2-Formylamino-cyclohexanol | 3731-14-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Formylamino-cyclohexanol
• 英文别名: N-(2-hydroxycyclohexyl)formamide
• CAS: 3731-14-4
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: PNSZZNWUYUSGCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  水合氯醛 、 2-Vinyloxy-cyclohexylamine 反应 0.17h， 生成 2-Formylamino-cyclohexanol 、 2-Methyl-hexahydro-benzooxazole-3-carbaldehyde
  参考文献：
  名称：

  Kukharev, B. F.; Stankevich, V. K.; Klimenko, G. R., Russian Journal of Organic Chemistry, 1995, vol. 31, # 5, p. 591 - 596

  摘要：

  DOI：

文献信息

• Therapeutic Agents
  申请人：Cheng Leifeng

  公开号：US20080319019A1

  公开（公告）日：2008-12-25

  The present invention relates to certain 1,2-diarylimidazoles of formula I and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及公式I的某些1,2-二芳基咪唑化合物的制备方法，它们在肥胖症、精神和神经系统疾病的治疗中的应用，以及它们的治疗用途和含有它们的制药组合物。
• AMIDINO-UREA SEROTONIN RECEPTOR LIGANDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND METHODS FOR THEIR SNYTHESIS
  申请人：Warner-Lambert Company LLC

  公开号：EP1332127A2

  公开（公告）日：2003-08-06
• THERAPEUTIC AGENTS
  申请人：AstraZeneca AB

  公开号：EP1831177A1

  公开（公告）日：2007-09-12
• 1,2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS
  申请人：AstraZeneca AB

  公开号：EP1833802A2

  公开（公告）日：2007-09-19
• [EN] AMIDINO-UREA SEROTONIN RECEPTOR LIGANDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND METHODS FOR THEIR SNYTHESIS<br/>[FR] LIGANDS DU RECEPTEUR DE LA SEROTONINE AMIDINO-UREE ET COMPOSITIONS, LEURS APPLICATIONS PHARMACEUTIQUES ET LEURS PROCEDES DE SYNTHESE
  申请人：WARNER LAMBERT CO

  公开号：WO2002036554A2

  公开（公告）日：2002-05-10

  Novel amidino-urea 5-HT7 receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites, or prodrugs thereof.